Oramed Pharmaceuticals (ORMP) Shares Outstanding (2011 - 2026)

Oramed Pharmaceuticals' Shares Outstanding (Entity) history runs 16 years deep, the most recent figure standing at $40.9 million for Q1 2026.

• Quarterly Shares Outstanding (Entity) changed 0.19% year-over-year to $40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.9 million (changed 0.19% YoY) and the FY2025 annual result came in at $39.3 million, down 1.61% from the prior year.
• Shares Outstanding (Entity) was $40.9 million for Q1 2026 at Oramed Pharmaceuticals, up from $39.3 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $40.9 million in Q1 2026 and bottomed at $38.6 million in Q1 2022.
• A 5-year average of $40.0 million and a median of $40.2 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) gained 4.29% — and 2025, when it decreased 1.61%.
• Oramed Pharmaceuticals' Shares Outstanding (Entity) stood at $39.6 million in 2022, then climbed by 1.96% to $40.3 million in 2023, then decreased by 1.04% to $39.9 million in 2024, then decreased by 1.61% to $39.3 million in 2025, then advanced by 4.2% to $40.9 million in 2026.
• Business Quant data shows ORMP's Shares Outstanding (Entity) at $40.9 million in Q1 2026, $39.3 million in Q4 2025, and $40.8 million in Q3 2025.